Shopping Cart
Remove All
Your shopping cart is currently empty
VII-31
Copy Product Info
😃Good
Catalog No. T62334Cas No. 2305757-96-2
Alias VII31
VII-31 is an activator of the NEDDylation pathway, capable of inducing apoptosis in MCF-7, PC-3, and MGC-803 cells.
VII-31
Copy Product Info😃Good
Catalog No. T62334Alias VII31Cas No. 2305757-96-2
VII-31 is an activator of the NEDDylation pathway, capable of inducing apoptosis in MCF-7, PC-3, and MGC-803 cells.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $149 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Appearance:Solid
Color:White
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | VII-31 is an activator of the NEDDylation pathway, capable of inducing apoptosis in MCF-7, PC-3, and MGC-803 cells. |
| Targets&IC50 | MGC-803 cells:0.09±0.01 μM, MCF-7 cells:0.10±0.006 μM, PC3 cells:1.15±0.28μM |
| In vitro | Methods: MGC803, MCF-7 and PC-3 cells were treated with VII-31 (0-200 μM, 48 hours), and cell viability was detected by MTT assay. Results: VII-31 inhibited the cell viability of MGC803, MCF-7 and PC-3 cells, with IC50 values of 0.09±0.01 μM, 0.10±0.006 and 1.15±0.28 μM, respectively. [1] |
| In vivo | Methods: VII-31 (10, 50, 150 mg/kg, subcutaneous injection, 28 days) was used to treat MGC803 cancer cells to establish a subcutaneous transplant tumor model of human gastric cancer. The tumor size was measured with a caliper to study its effect on tumors in mice. Results: Within 28 days after the first treatment, the tumor volume of mice in the VII-31 treatment group was significantly smaller than that in the control group; the tumor weight of the 50 mg/kg VII-31 treatment group was about 36% lower than that in the control group, and the tumor weight of the 100 mg/kg VII-31 and 150 mg/kg VII-31 treatment groups was 42% and 46% lower than that in the control group, respectively. VII-31 was able to inhibit the progression of tumors in mice and had no obvious toxicity to mice. [1] |
| Synonyms | VII31 |
| Molecular Weight | 427.51 |
| Formula | C23H25NO5S |
| Cas No. | 2305757-96-2 |
| Smiles | O=C(N(C1=CC(OC)=C(OC)C(OC)=C1)CC2=CC=C(OC)C=C2)CC=3SC=CC3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (467.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy VII-31 | purchase VII-31 | VII-31 cost | order VII-31 | VII-31 chemical structure | VII-31 in vivo | VII-31 in vitro | VII-31 formula | VII-31 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.